IL-7Rα confers susceptibility to experimental autoimmune encephalomyelitis

Genes and Immunity

Volumn 12, Issue 1, 2011, Pages 1-14

  Walline, C C ^a   Kanakasabai, S ^a   Bright, J J ^a,b  

^a METHODIST RESEARCH INSTITUTE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

EAE MS; IL 7R ; inflammation; neuroimmunology; Th1 Th17 response

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 7 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE MODEL; DISEASE PREDISPOSITION; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; IMMUNOPATHOGENESIS; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TH17 CELL;

ANIMALS; AUTOANTIGENS; CD4-POSITIVE T-LYMPHOCYTES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; INTERLEUKIN-4; MALE; MICE; MYELIN SHEATH; RECEPTORS, INTERLEUKIN-7; T-LYMPHOCYTES, REGULATORY;

MUS;

EID: 78751647205     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2010.49     Document Type: Article

References (54)

1. Whitacre CC, Reingold SC, O'Looney PA. A gender gap in autoimmunity. Science 1999; 283: 1277-1278.
2. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000; 343: 938-952.
3. Hemmer B, Cepok S, Nessler S, Sommer N. Pathogenesis of multiple sclerosis: an update on immunology. Curr Opin Neurol 2002; 15: 227-231.
4. Steinman L, Martin R, Bernard C, Conlon P, Oksenberg JR. Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. Annu Rev Neurosci 2002; 25: 491-505.
5. Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, De Jager PL et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007; 357: 851-862.
6. Gregory SG, Schmidt S, Seth P, Oksenberg JR, Hart J, Prokop A et al. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet 2007; 39: 1083-1091.
7. Lundmark F, Duvefelt K, Iacobaeus E, Kockum I, Wallstrom E, Khademi M et al. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat Genet 2007; 39: 1108-1113.
8. Svejgaard A. The immunogenetics of multiple sclerosis. Immunogenetics 2008; 60: 275-286.
9. Akkad DA, Hoffjan S, Petrasch-Parwez E, Beygo J, Gold R, Epplen JT. Variation in the IL7RA and IL2RA genes in German multiple sclerosis patients. J Autoimmun 2009; 32: 110-115.
10. D'Netto MJ, Ward H, Morrison KM, Ramagopalan SV, Dyment DA, DeLuca GC et al. Risk alleles for multiple sclerosis in multiplex families. Neurology 2009; 72: 1984-1988.
11. Zuvich RL, McCauley JL, Oksenberg JR, Sawcer SJ, De Jager PL, Aubin C et al. Genetic variation in the IL7RA/IL7 pathway increases multiple sclerosis susceptibility. Hum Genet 2010; 127: 525-535.
12. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+T reg cells. J Exp Med 2006; 203: 1701-1711.
13. Sojka DK, Huang YH, Fowell DJ. Mechanisms of regulatory T-cell suppression-a diverse arsenal for a moving target. Immunology 2008; 124: 13-22.
14. Peschon JJ, Morrissey PJ, Grabstein KH, Ramsdell FJ, Maraskovsky E, Gliniak BC et al. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J Exp Med 1994; 180: 1955-1960.
15. Kim K, Lee CK, Sayers TJ, Muegge K, Durum SK. The trophic action of IL-7 on pro-T cells: inhibition of apoptosis of pro-T1, -T2, and -T3 cells correlates with Bcl-2 and Bax levels and is independent of Fas and p53 pathways. J Immunol 1998; 160: 5735-5741.
16. Leonard WJ, Noguchi M, Russell SM. Sharing of a common gamma chain, gamma c, by the IL-2, IL-4, and IL-7 receptors: implications for X-linked severe combined immunodeficiency (XSCID). Adv Exp Med Biol 1994; 365: 225-232.
17. DiSanto JP, Muller W, Guy-Grand D, Fischer A, Rajewsky K. Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain. Proc Natl Acad Sci USA 1995; 92: 377-381.
18. Mazel S, Burtrum D, Petrie HT. Regulation of cell division cycle progression by bcl-2 expression: a potential mechanism for inhibition of programmed cell death. J Exp Med 1996; 183: 2219-2226.
19. Watanabe N, Hanabuchi S, Marloie-Provost MA, Antonenko S, Liu YJ, Soumelis V. Human TSLP promotes CD40 ligand-induced IL-12 production by myeloid dendritic cells but maintains their Th2 priming potential. Blood 2005; 105: 4749-4751.
20. Ziegler SF, Liu YJ. Thymic stromal lymphopoietin in normal and pathogenic Tcell development and function. Nat Immunol 2006; 7: 709-714.
21. Al-Shami A, Spolski R, Kelly J, Fry T, Schwartzberg PL, Pandey A et al. A role for thymic stromal lymphopoietin in CD4(+) T cell development. J Exp Med 2004; 200: 159-168.
22. Bayer AL, Lee JY, de la Barrera A, Surh CD, Malek TR. A function for IL-7R for CD4+CD25+Foxp3+ T regulatory cells. J Immunol 2008; 181: 225-234.
23. Bright JJ, Du C, Sriram S. Tyrphostin B42 inhibits IL-12-induced tyrosine phosphorylation and activation of Janus kinase-2 and prevents experimental allergic encephalo-myelitis. J Immunol 1999; 162: 6255-6262.
24. Natarajan C, Bright JJ. Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes. J Immunol 2002; 168: 6506-6513.
25. Natarajan C, Bright JJ. Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic ence-phalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation. Genes Immun 2002; 3: 59-70.
26. Mo C, Chearwae W, O'Malley JT, Adams SM, Kanakasabai S, Walline CC et al. Stat 4 isoforms differentially regulate inflammation and demyelination in experimental allergic encephalomyelitis. J Immunol 2008; 181: 5681-5690.
27. Bergamaschi R. Prognosis of multiple sclerosis: clinical factors predicting the late evolution for an early treatment decision. Expert Rev Neurother 2006; 6: 357-364.
28. Pokryszko-Dragan A, Gruszka E, Bilinska M, Dubik-Jezierzanska M. Secondary progressive multiple sclerosis-clinical course and potential predictive factors. Neurol Neurochir Pol 2008; 42: 6-11.
29. Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, Kakuta S et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 2006; 177: 566-573.
30. Bebo Jr BF, Schuster JC, Adlard K, Vandenbark AA, Offner H. Interleukin 7 is a potent costimulator of myelin specific Tcells that enhances the adoptive transfer of experimental autoimmune encephalomyelitis. Cytokine 2000; 12: 324-331.
31. Van Roon JA, Glaudemans KA, Bijlsma JW, Lafeber FP. Interleukin 7 stimulates tumour necrosis factor alpha and Th1 cytokine production in joints of patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62: 113-119.
32. Van Roon JA, Verweij MC, Wijk MW, Jacobs KM, Bijlsma JW, Lafeber FP. Increased intraarticular interleukin-7 in rheumatoid arthritis patients stimulates cell contact-dependent activation of CD4(+) T cells and macrophages. Arthritis Rheum 2005; 52: 1700-1710.
33. Gran B, Zhang GX, Yu S, Li J, Chen XH, Ventura ES et al. IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination. J Immunol 2002; 169: 7104-7110.
34. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003; 421: 744-748.
35. Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 2002; 16: 779-790.
36. Li J, Gran B, Zhang GX, Rostami A, Kamoun M. IL-27 subunits and its receptor (WSX-1) mRNAs are markedly up-regulated in inflammatory cells in the CNS during experimental autoimmune encephalomyelitis. J Neurol Sci 2005; 232: 3-9.
37. Anderson AC, Reddy J, Nazareno R, Sobel RA, Nicholson LB, Kuchroo VK. IL-10 plays an important role in the homeostatic regulation of the autoreactive repertoire in naive mice. J Immunol 2004; 173: 828-834.
38. Bettelli E, Das MP, Howard ED, Weiner HL, Sobel RA, Kuchroo VK. IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10-and IL-4-deficient and transgenic mice. J Immunol 1998; 161: 3299-3306.
39. Begolka WS, Vanderlugt CL, Rahbe SM, Miller SD. Differential expression of inflammatory cytokines parallels progression of central nervous system pathology in two clinically distinct models of multiple sclerosis. J Immunol 1998; 161: 4437-4446.
40. Brocke S, Gijbels K, Allegretta M, Ferber I, Piercy C, Blankenstein T et al. Treatment of experimental encephalo-myelitis with a peptide analogue of myelin basic protein. Nature 1996; 379: 343-346.
41. Mann-Chandler MN, Kashyap M, Wright HV, Norozian F, Barnstein BO, Gingras S et al. IFN-gamma induces apoptosis in developing mast cells. J Immunol 2005; 175: 3000-3005.
42. Dieckmann D, Bruett CH, Ploettner H, Lutz MB, Schuler G. Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells. J Exp Med 2002; 196: 247-253.
43. Jonuleit H, Schmitt E, Kakirman H, Stassen M, Knop J, Enk AH. Infectious tolerance: human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells. J Exp Med 2002; 196: 255-260.
44. Zheng SG, Wang JH, Gray JD, Soucier H, Horwitz DA. Natural and induced CD4+CD25+ cells educate CD4+CD25-cells to develop suppressive activity: the role of IL-2, TGF-beta, and IL-10. J Immunol 2004; 172: 5213-5221.
45. Murai M, Turovskaya O, Kim G, Madan R, Karp CL, Cheroutre H et al. Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat Immunol 2009; 10: 1178-1184.
46. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4: 330-336.
47. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-1061.
48. Gambineri E, Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr Opin Rheumatol 2003; 15: 430-435.
49. Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4+CD25+ Tregulatory cells. Nat Immunol 2003; 4: 337-342.
50. Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001; 27: 68-73.
51. Mazzucchelli R, Hixon JA, Spolski R, Chen X, Li WQ, Hall VL et al. Development of regulatory T cells requires IL-7Rastimulation by IL-7 or TSLP. Blood 2008; 112: 3283-3292.
52. Huber S, Schrader J, Fritz G, Presser K, Schmitt S, Waisman A et al. P38 MAP kinase signaling is required for the conversion of CD4+CD25- T cells into iTreg. PLoS ONE 2008; 3: e3302.
53. Stephens LA, Malpass KH, Anderton SM. Curing CNS autoimmune disease with myelin-reactive Foxp3+ Treg. Eur J Immunol 2009; 39: 1108-1117.
54. Raikwar HP, Muthian G, Rajasingh J, Johnson C, Bright JJ. PPARgamma antagonists exacerbate neural antigen-specific Th1 response and experimental allergic encephalomyelitis. J Neuroimmunol 2005; 167: 99-107.